OUR NEW PROFILE IS: (NASDAQ: COSM)
COSM just posted $3.7 million in profits for the first six months of 2022
MASSIVE SHIFT TO PREVENTIVE HEALTHCARE COULD PROPEL THE GLOBAL NUTRACEUTICALS MARKET TO $1 TRILLION BY 2030
Yahoo has the Market cap on COSM at just 9.6M
The Company Just Achieved Annual Revenues of $56 Million and Reported a 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022
___________________
Hello Everyone,
We have another profile for today’s session that we want you to take a look at.
This one has a number of catalysts worth looking at for today.
It trades on a major exchange and is sitting under .50 and in a profitable financial situation.
I want you to pull up COSM immediately.
Take a look at some of the catalysts in play:
Amazon: Cosmos Health Inc. (COSM) just launched its “Sky Premium Life” nutritional supplement products on Amazon in the United States (25), tapping into the 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)
Booming Market: It is estimated that 77% of Americans use dietary supplements (27)while the U.S. nutraceutical market is expected to hit $138.0 billion by 2027(25) and the global nutraceuticals market is expected to reach $1 trillion by 2030. (23)
Gross Profits: Cosmos Health Inc. (COSM) just reported a 202.42% increase in adjusted EBITDA with gross profits increasing by 23.0% to $3.7 million for the six months ended June 30, 2022.(26)
Value: Cosmos Health Inc. (COSM) is a very small company with a market cap just under $9.3 million according to Yahoo finance. (31) Not bad for a company that just posted $3.7 million in profits for the first six months of 2022. (26)
Upside Potential: The company was listed on the NASDAQ on February 28th, 2022 when it reached an intraday high of $3.92 and closed around $.36 on September 2nd, 2022 according to Barchart.com. That means Cosmos Health Inc. (COSM) is approximately 988% off its 52-week high. Can you say potential upside?.
Couple all of this with a tiny market cap and strong financial news, this one has potential moving forward.
The rising demand for dietary supplements and functional foods is expected to be a major driving force in the preventive healthcare market. (19)
In addition, a positive outlook toward medical nutrition, given its growing use in the treatment of cardiovascular disorders and malnutrition, is likely to boost the growth of the nutraceuticals market in the coming years. (19)
The rising geriatric population, rising healthcare costs, changing lifestyles, food innovation, and expectations regarding higher prices will propel the growth of the nutraceuticals market in the upcoming years. (19)
Consumers have a very positive attitude toward nutraceuticals, nutritional supplements, and functional foods – owing to the additional health and wellness benefits that these products provide, driving the market’s growth. (19)
During the pandemic period, demand for nutraceuticals expanded globally due to the flexibility of storage choices, the need for combination formulations with various benefits, increasing consumer education levels, educated consumers, and the growth in health concerns among informed consumers.(19)
Moreover, rising healthcare costs, combined with an aging global population, are expected to drive the global nutraceuticals industry’s growth over the next decade. (19)
One company that could benefit from the massive shift to Nutraceuticals is Cosmos Health Inc. (NASDAQ: COSM). (18)
Cosmos Health Inc. is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. The company is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” (21)
Cosmos Health Inc. (NASDAQ: COSM) offers broad exposure to the pharmaceutical sector as well, through a broad line of branded generics and over-the-counter (OTC) medications. (21)
In addition, Cosmos Health Inc. is involved in the healthcare distribution sector through its subsidiaries in Greece and the UK serving retail pharmacies and wholesale distributors.
The company is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. (21)
Cosmos Health Inc. (NASDAQ: COSM) specifically focuses on the following business segments:
- Nutraceuticals: The direct sale and distribution of nutraceuticals offer greater margins than pharmaceutical product distribution. Cosmos Health Inc. is always looking to expand their proprietary portfolio of products that it distributes to maximize its margins. Cosmos Health Inc. also provides its customers with a larger portfolio of products that they can source from a single vendor. In addition to being wholesalers for supplements and related products, Cosmos Health Inc. has created its own brand of products to sell to its current customer base. The company’s wholesale business gives insight to what products are in demand and it communicates with its customer base to identify which products to develop. Cosmos Health’s own brand of products would carry significantly higher margins than simply serving as a wholesaler for other brands. (21)
- Branded Pharmaceuticals: Branded pharmaceutical products are an important product category that Cosmos Health Inc. imports and exports. The company is constantly evaluating product availability, pricing, demand trends, and patent expirations to maximize its performance. As the patents for branded products near expiration, the generic equivalents enter the market place and the demand for those branded products start to decrease. Cosmos Health Inc. monitors these cycles closely and always looks to find value in pricing fluctuations caused by the patent expirations as the generic equivalents enter the market. (21)
- Generic Pharmaceuticals: Generic pharmaceutical products are a substantial product category that Cosmos Health Inc. imports and exports. The company applies the same discipline to generics that it does to the branded. Cosmos Health Inc. evaluates the demand and supply dynamics of branded products as their patents expire. This insight sheds light on the demand of generic products that take their place. Understanding the historical and market specific characteristics of generic product demand provides insight that the company uses to give guidance to its vendors that source its generic drug exports. (21)
- Research & Development: Cosmos Health Inc. is committed to strategic R&D across each business unit with a particular focus for nutraceutical products with inherently lower risk profiles and clearly defined regulatory pathways. The company is constantly evaluating the demand of food supplements in the markets that it currently distributes pharmaceutical products to. This research and analysis determines which food and nutritional supplements it chooses to develop as well as their formulations. This approach maximizes the probability of successfully competing with other brands in the marketplace. (21)
- Acquisitions: Cosmos Health Inc. regularly evaluates acquisition targets that would allow the company to expand its distribution reach and/or vertically integrate into the supply chain of the products that it currently distributes. In addition to focusing on organic growth drivers, the company is actively pursuing acquisitions that offer long-term revenue growth, margin expansion through synergies, and the ability to maintain a flexible capital structure. (21)
- Local & Direct to Pharmacy Wholesale: Cosmos Health Inc. is expanding into the full-line wholesale distribution business through acquisition. Full-line pharmaceutical wholesalers provide the local markets with branded pharmaceuticals, generic pharmaceuticals, over-the-counter (OTC) medicines, vitamins and food supplements. By expanding the company’s pharmaceutical distribution business, Cosmos Health Inc. will have a better ability to source more branded and generic products directly from manufacturers and sell its vitamins, food supplements and cosmetic products directly to pharmacies for better prices. The company expects this expansion to increase its sales and profit margins as its vertically integrates into the supply chain. (21)
_____
Take a look at the 3 month chart. It has been moving forth in a fairly tight channel on low interest. We saw it explode out of it’s comfort range when interest poured in. This could have been for a number of reasons.
The Global Nutraceuticals Market Expected To Reach $1 Trillion by 2030 (23)
Cosmos Health Inc. (NASDAQ: COSM) could potentially be well positioned for this unprecedented opportunity in the nutraceuticals market.
Market Overview: Nutraceuticals is a comprehensive umbrella term which is used to label any product acquired from food origin with additional health advantages over and above the basic nutritious value available in foods. (23)
Nutraceuticals can be regarded as non-precise biological remedies used to boost general health, regulate indications and avert malignant developments. (23)
Nutraceuticals can be segmented on the foundation of their natural basis, pharmacological circumstances, as well as chemical structure of the products. Most often nutraceuticals are organized in the following classes: functional food, dietary supplements, pharmaceuticals, and medicinal food. (23)
According to a report from Precedence Research, crucial factors accountable for nutraceutical market growth are: (23)
- Constant innovations in health sciences
- Increasing need for preventive healthcare
- Growing awareness regarding health and well-being
- Development of function-specific antioxidants
- Increasing prevalence of lifestyle related disorders
- Increasing number of fitness centers in developing regions
- Increasing disposable income
- Rise of e-commerce industry
Cosmos Health Inc. (COSM) Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States (25)
In August 2022, Cosmos Health Inc. launched the first of its “Sky Premium Life” products on Amazon in the United States. The company targets having all 85 product SKUs listed on Amazon by year end. (25)
“We are excited to officially launch our Sky Premium Life products on Amazon in the United States,” stated Greg Siokas, Chief Executive Officer of Cosmos Health. (25)
“Sky Premium Life products are currently being shipped and will arrive in the U.S. in early September. Importantly, we have executed on our strategy in the U.S. by launching our products on Amazon in the third quarter of 2022 as stated previously. We expect to have all 85 SKUs listed on Amazon by the end of this year. We are accelerating our global roll-out strategy as we launch our products worldwide. Earlier this year, we successfully introduced our products on Amazon in the U.K. and Singapore. Our key objective is to grow internationally, as we continue to leverage our robust global logistics and distribution capabilities, while expanding our customer base worldwide.” (25)
To view the full Sky Premium Life product line click here.
Amazon News: This could prove to be a complete game changer for Cosmos Health Inc.(COSM) as the platform has 90 million Amazon Prime subscribers in the US, and more than 300 million active customers worldwide. (24)
Cosmos Health Inc. (COSM) Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022 (26)
“We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively.”
“During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022. We look forward to launching our high-quality nutraceutical products into other new international markets this year, by leveraging our robust global logistics and distribution capabilities.”
“Most recently we announced that we have rebranded and changed our name to Cosmos Health to better reflect the Company’s evolution into an innovative global healthcare group with a focus on improving people’s lives. Through our vertically integrated ecosystem, the enhancements we made with cutting edge technologies for the development of our pharmaceutical and nutraceutical products enable the Company to implement our goal of becoming a global healthcare group, committed to human health needs.”
“The Cosmos Health brand marks a new chapter in the Company’s evolution and better reflects our commitment towards a leading, highly scalable and innovative global healthcare group based on our R&D partnerships, fully licensed production facilities and fast deployment to distribution channels. This is in alignment with the Company’s recent announcements about our R&D partnership with CloudPharm and proposed acquisition of Cana Laboratories, a fully licensed Good Manufacturing Practices (GMP) medical manufacturing facility with outstanding scientific personnel, as we execute on our goal of becoming a leading global healthcare group,” concluded Greg Siokas, Chief Executive Officer of Cosmos Health.
For the fifth year in a row, US News & World Report in January of 2022 ranked the Mediterranean diet No. 1 in multiple categories, including best for heart health, best for diabetes and best overall diet for weight loss. (12)
Even the prestigious Mayo clinic has declared the diet heart healthy (14) and for good reason…
The Mediterranean Basin has a very unique climate found in only a few places in the world. It is sunny, hot, and dry in the summer, with cold and wet winters.(15) That’s what makes the herbs, plants and pretty much everything from the region so in-demand.
On April 12, 2022, Sky Premium Life, Cosmos’ proprietary luxury nutritional supplement product line, launched Mediterranation, a new premium line of nutritional supplements. That can leverage the awareness of the extremely popular Mediterranean diet with a full line of supplements. (13)
High demand. High quality. Excellent revenue potential.
“There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We carefully selected ingredients that have demonstrated positive effects, ranging from gut health, to aging, diabetes and cardiovascular disease,”
“We created Mediterranation with good health in mind, utilizing unique formulations, and a specialized extraction process following strict pharmaceutical standards. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels.” (13)
Cosmos Health Inc. (COSM) Invests in Advanced Technologies to Expand Productivity(11)
A few months back, Cosmos made a HUGE announcement in regards to installing a “State-of-the-Art” automated fulfillment system at their logistics center in Greece.
The fully automated fulfillment system is designed to process complex orders with precision and speed, leading to increased performance while drastically lowering error rates.
The system can process up to 40,000 products per hour and can accommodate a variety of packaging shapes and sizes.
Greg Siokas, Chief Executive Officer of Cosmos Holdings, stated,
“With a fully robotic system in place, CosmoFarm’s logistic center can now process orders at higher speeds and higher quality, even at peak times. This is critical to maintain the quality of our service while scaling our product offerings and client base. This installation reflects our commitment to invest in advanced technologies that substantially expand our current productivity and throughput, supporting our growth and improving the overall efficacy of our deliverables.” (11)
CosmoFarm, headquartered in Athens, Greece is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. CosmoFarm’s core activity is sourcing, procuring, and distributing branded and generic medicines, over-the-counter (OTC) pharmaceuticals, food supplements, and medical devices to its growing network of more than 1,130 pharmacies.
Now, to the Bread and Butter: Cosmos Health Inc. (COSM) Has a Comprehensive Strategy
Sourcing and distribution, including specialty pharmaceuticals, is what Cosmos sees as the anchor of its growth and position in the pharmaceutical supply channel. Cosmos provides superior services and delivers value-added products, which improve the efficiency and competitiveness of healthcare providers. In turn, this aids the pharmaceutical supply channel to better provide healthcare to patients.
Cosmos Health Inc. (COSM) is Also Very Well Known for the Following 3 Subsidiaries Under its Belt: (8)
Sky Pharm SA:
Sky Pharm SA is a Thessaloniki, Greece-based pharmaceutical trading firm. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. Cosmos buys from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers and then exports them to European markets where demand and prices are substantially higher.
DHNDecahedron Ltd.:
Decahedron Ltd. is a UK-incorporated pharmaceutical wholesaler. It is audited by the MHRA under European GDP (Good Distribution Practices). It is also a full member of the EAEPC and has been audited by TÜV on its behalf. Decahedron imports and exports branded, generic and unlicensed POM, OTCs, and medical devices worldwide. It also participates in governmental tenders and registers dossiers in new territories. This subsidiary’s network consists of roughly 25 clients and vendors expanding to 9 countries, including Germany, UK, Denmark, The United Arab Emirates, Germany, Italy, France, Singapore, and Ireland.
Cosmofarm:
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area.
Could Cosmos Health Inc. (COSM) Climb 988% Back To $3.92?
Taking a look at the chart above (from StockCharts.com) and observing the technical analysis you can clearly see the following moving averages:
– 50 day moving average at $.38
– 120 day moving average at $.94
– 20 day exponential moving average $.36 (key line of potential resistance)
But what you don’t see – is what this actually means in dollars and cents.
Meaning, that if Cosmos Health Inc. (COSM) trends above its first line of resistance at the $.36 range… then the next line of potential resistance may be all the way at $.94, which, if reached, would represent an approximate 161% potential move.
Furthermore, if Cosmos Health Inc. (COSM) were to climb back to $3.92 from $.36 (closing price as of 9/2/22), it would represent an approximate 988% move.
Now, I’m not saying that Cosmos Health Inc. (COSM) is going to reach those levels today, tomorrow, or next week, but you need to be aware of its potential upside from current trading levels.
You see, from a technical analysis perspective, Cosmos Health Inc. (COSM) could be at the beginning of what’s called a “Descending Triangle Breakout Strategy.”
…And by definition, the “Descending Triangle Breakout Strategy,” as the name suggests, involves the anticipation of a breakout from the descending triangle pattern. (31)
This strategy uses a very simple combination of trading volumes and asserting the trend, which can be used to capture short term vertical moves.(31)
The basic premise of using this strategy is to look at volume once you’ve identified the pattern. You can typically observe that volume begins to diminish toward the end of the descending triangle pattern formation. (31)
Massive Shift To Preventive Healthcare Could Propel The Global Nutraceuticals Market To $1 Trillion By 2030. (17)
One company that could be extremely well positioned for this unprecedented opportunity is Cosmos Health Inc. (NASDAQ: COSM)…(18)
RECENT NEWS
|
Cosmos Health to Launch Sky Premium Life Nutritional Supplement Products in Germany and Austria via Amazon and Ebay
|
|
Cosmos Health Launches First Sky Premium Life Nutritional Supplement Products on Amazon in the United States
|
|
Cosmos Health Reports 202.42 % Increase in Adjusted EBITDA and Positive Operating Income for the First Half of 2022
|
|
Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company’s Evolution into an Innovative Global Healthcare Group, Driven by One Purpose: Improving People’s Lives
|
|
Cosmos Holdings Appoints Dr. Manfred Ziegler to its Advisory Board
|
|
Cosmos Holdings Announces Agreement to Acquire Cana Laboratories, a Legacy European Pharmaceutical Company Established in 1928; Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands
|
|
Cosmos Holdings Subsidiary Granted Full Membership in PAGB, A UK-based Consumer Healthcare Association
|
|
Cosmos Holdings Appoints Dr. Panagiotis Zoumpoulakis to its Advisory Board
|
|
Cosmos Holdings to Acquire LIFE NLB Portfolio of Bone Health Products that Target the Gastrointestinal Microbiome
|
|
Cosmos Holdings Announces Strategic R&D Partnership with Cloudpharm P.C. to Study the Human Gastrointestinal Microbiome and Launch Related Products Targeting on Obesity and Other Gut-Related Disorders
|
|
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon in the United States
|
|
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022
|
|
Cosmos Holdings to Launch Sky Premium Life Nutritional Supplements on Amazon Canada
|
|
Cosmos Holdings Appoints Finance Veteran Dr. Anastasios Aslidis to the Board of Directors and as a Member of the Board’s Audit Committee
|
MANAGMENT
Mr. Grigorios Siokas has over 15 years’ experience in the pharmaceutical industry. Since 2014, he has served as the CEO and Operations Manager of SkyPharm SA a wholly-owned subsidiary of the Company. SkyPharm SA is a pharmaceutical company located in Greece that mainly exports medicines from Greece to other European countries, such as Germany, England and Denmark.
Prior to 2014, Mr. Siokas worked in a variety of sectors of the pharmaceutical industry mostly in the trading of medicines in Greece and other European countries. Additionally, since 2000 he has been a major shareholder in various pharmaceutical companies such as: Ippokratis Pharmaceuticals, (annual sales of over € 78 million); Thrakis Pharmaceuticals, (annual sales of over € 20 million); Thessalias Pharmaceuticals, (annual sales of over € 18 million); and ZED Pharma SA, (annual sales of over € 35 million).
During the 1990s, Mr. Siokas founded and operated a marble wholesale import – export company in Germany. Within a period of two years he became the 4th biggest Greek marble importer in Germany. He also ran a Tour Operation with many different airlines, serving millions of customers.
Mr. Grigorios Siokas has Bachelor’s Degree in Geology from the Aristotle University of Thessaloniki, Greece. He received a Master’s in management and finance from the University of Stuttgart and the University of Tuebigen, Germany and has served in the Greek Army.
Dimitrios Goulielmos joined us as CEO and Director on September 27, 2013. Since January 1991, he has been the principal attorney at the law firm of Goulielmos D. & Partners. He contributes to the Board the benefits of his legal, academic, and business background.
Mr. Goulielmos is a fourth generation attorney. He received his law degree with Excellency from the Aristotle University of Thessaloniki in 1988. He did post graduate studies for International transactions and Company law at Paris, France and at the LSE of London, England.
In 2004 he was elected Vice-president of EUROPECHE, the organization that was established by the European Committee for the consultation and proposal of solutions in the sector of Community Fishery.
The same year he was also elected as National representative of Hellas in the MEDISAMAK, the organization responsible for all Mediterranean countries, in the sector of Fishery.
In year 2007 he was re-elected as Vice-president of EUROPECHE. He is a member of the social dialogue group of ACFA, of EU on labor affairs.
He is an honorary lifetime member of International Who’s Who Historical Society.
Mr. Goulielmos has extensive experience in law, international deals, mergers, acquisitions, negotiations, international application of licenses, and real estate management which he will contribute to the Board.
Mr. Demetrios G. Demetriades was elected as Secretary and Director of the Company.
Since January 2003, Mr. Demetriades, age 48, has been Director of Highlander Spring Trading Ltd, a trading company.
From November 2000 to December 2002 he was Marketing Director of Eurolink Securities Ltd which was involved in trading in the Cyprus Stock Exchange.
From January 1995 to November 2000 he was Supervising Officer of Laiki Factors Ltd, a financing company.
As a member of the board, Mr. Demetriades contributes the benefits of his trading, executive leadership and management experience.
Sincerely,
The Viral Stocks Team
